Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -40

Why Moderna stock plunged despite positive cancer vaccine trial results?

Clinical trial results AI-generated analysis

πŸ“‰ Moderna stock plunged as much as 25% after leaked partial data from its Phase 3 cancer vaccine trial circulated online ahead of a scheduled presentation.

πŸ”¬ The leaked results showed clinically meaningful efficacy, with the vaccine reducing melanoma recurrence or death risk by 42% when combined with Merck's Keytruda.

⚠️ Investors attributed the sell-off to 'expectations vs. perfection,' fearing that the full dataset might show weaker benefits in distant metastasis subgroups than anticipated.

🀝 The intismeran autogene is being developed by Moderna in partnership with Merck for high-risk melanoma patients alongside Keytruda immunotherapy.

πŸ“… Trading was briefly halted due to volatility before the stock recovered slightly, trading down 16% as the full dataset embargo was lifted.

πŸ₯ The European Society for Medical Oncology confirmed the study abstract's embargo had been breached and later lifted the restriction on the full dataset.

Bullish Signals
  • The leaked Phase 3 data demonstrated clinically meaningful efficacy, showing a hazard ratio of 0.58 for recurrence or death and an 82% recurrence-free survival rate at two years versus 70% with Keytruda alone.
  • The vaccine reduced the risk of melanoma recurrence or death by 42% when administered alongside Merck's Keytruda, validating the combination therapy approach.
Risk Factors
  • Moderna shares plunged as much as 25% due to elevated market expectations and sell-the-news volatility following the leak of partial trial results.
  • Investors expressed concern that the full Phase 3 dataset might reveal weaker benefits in distant metastasis subgroups, potentially turning the move into a real efficacy miss.
Full Analysis
Moderna (MRNA) shares experienced a sharp decline of up to 25% following the premature leak of partial data from its Phase 3 clinical trial for intismeran autogene, a cancer vaccine developed in partnership with Merck. Despite analysts characterizing the leaked results as clinically meaningful, showing a 42% reduction in melanoma recurrence or death risk compared to Keytruda alone, the stock sold off due to elevated market expectations and volatility. The trial data indicated a hazard ratio of 0.58 for recurrence or death and an 82% recurrence-free survival rate at two years versus 70% with Keytruda monotherapy. However, investors reacted negatively to the news, fearing that the full dataset might reveal weaker benefits in distant metastasis subgroups or other efficacy misses that could undermine the drug's value proposition. Trading was briefly halted due to the severity of the price movement before recovering slightly to a 16% drop at the time of reporting. The European Society for Medical Oncology confirmed the embargo breach and subsequently lifted restrictions on the full dataset, setting the stage for further analysis once the complete results are presented at the conference.